Evidence map›Paper›PMID 34385707›Full record

Trial reportNature medicine2021

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Tien Dam, Adam L Boxer, Lawrence I Golbe, Günter U Höglinger, Huw R Morris, Irene Litvan, Anthony E Lang, Jean-Christophe Corvol, Ikuko Aiba, Michael Grundman and 11 more

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03068468 (A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy), which is not on this map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03068468 phase2terminatednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

TypeinterventionalSponsorBiogenRan2017 to 2020Enrolled490ConditionsSupranuclear Palsy, ProgressiveArmsBIIB092, Placebo
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 134 citations in OpenAlex.

  1. Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Promoter mutagenesis and a massively parallel reporter screen of thebioRxiv : the preprint server for biology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  16. Article
  17. Article
  18. Brain Networks Route Neurodegeneration Patterns in Patients with Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  19. Review
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 6 countries.

Tien DamBiogen, Cambridge, MA, USA. tien.dam@biogen.com.ORCID http://orcid.org/0000-0002-7786-5825
Adam L BoxerMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Lawrence I GolbeRutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Günter U HöglingerDepartment of Neurology, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0001-7587-6187
Huw R MorrisNational Hospital for Neurology and Neurosurgery, London, UK.ORCID http://orcid.org/0000-0002-5473-3774
Irene LitvanUniversity of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.ORCID http://orcid.org/0000-0002-3485-3445
Anthony E LangEdmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.
Jean-Christophe CorvolSorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France.
Ikuko AibaDepartment of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.
Michael GrundmanUniversity of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.
Lili YangBiogen, Cambridge, MA, USA.
Beth Tidemann-MillerBiogen, Cambridge, MA, USA.
Joseph KupfermanBiogen, Cambridge, MA, USA.
Kristine HarperBiogen, Cambridge, MA, USA.
Kubra KamisogluBiogen, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6620-0564
Michael J WaldBiogen, Cambridge, MA, USA.
Danielle L GrahamBiogen, Cambridge, MA, USA.
Liz GedneyBiogen, Cambridge, MA, USA.
John O'GormanBiogen, Cambridge, MA, USA.
Samantha Budd HaeberleinBiogen, Cambridge, MA, USA.
PASSPORT Study Group
Biogen (United States) · USCentre National de la Recherche Scientifique · FRGerman Center for Neurodegenerative Diseases · DEHigashi Nagoya National Hospital · JPNational Hospital for Neurology and Neurosurgery · GBRutgers, The State University of New Jersey · USUniversity of California, San Francisco · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468) evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive supranuclear palsy (PSP). In total, 486 participants dosed were assigned to either gosuranemab (n = 321) or placebo (n = 165). Efficacy was not demonstrated on adjusted mean change of PSP Rating Scale score at week 52 between gosuranemab and placebo (10.4 versus 10.6, P = 0.85, primary endpoint), or at secondary endpoints, resulting in discontinuation of the open-label, long-term extension. Unbound N-terminal tau in cerebrospinal fluid decreased by 98% with gosuranemab and increased by 11% with placebo (P < 0.0001). Incidences of adverse events and deaths were similar between groups. This well-powered study suggests that N-terminal tau neutralization does not translate into clinical efficacy.

Indexed as

AgedAntibodies, Monoclonal, HumanizedDouble-Blind MethodFemaleHumansMalePneumoniaSupranuclear Palsy, Progressivetau ProteinsTreatment OutcomeAntibodies, Monoclonal, HumanizedgosuranemabMAPT protein, humantau Proteins

Identifiers

PMID34385707
OpenAlexW3191692701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.